Drug Database
AL

aluminium hydroxide (Pangramin Depot)

✓ Approved

ALK-Abello · 治疗药物

什么是 aluminium hydroxide?

aluminium hydroxide 是一种治疗药物,由ALK-Abello研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Pangramin Depot
公司ALK-Abello
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

治疗适应症

aluminium hydroxide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved

相关研究文献

PubMedCell death & disease2026-11-19

Loss of SNORD104-guided rRNA methylation promotes early adaptation to crizotinib in lung adenocarcinoma.

Mourksi Nour-El-Houda NE, Isaac Caroline C, Ripoll Julie J, Radermecker Julie J et al.

The ribosome, long considered an invariant actor of gene expression, recently emerged as a contributor to translational control through chemical modifications of ribosomal RNAs (rRNAs). These modifications are guided by small nucleolar RNAs (snoRNAs), which direct modifying enzymes to specific rRNA positions. Here, we report that lung adenocarcinoma (LUAD) cells that are resistant to tyrosine kinase inhibitors (TKIs) reshape both their translational program and rRNA 2'O-ribose methylation (2'Ome) profiles. EML4-ALK-positive LUAD cells that are resistant to crizotinib (ALK inhibitor) exhibit reduced global protein synthesis and a change in selective translation of mRNAs, encoding proteins previously linked to resistance. These cells show concomitant reduction in SNORD104 and 2'Ome at its associated 28S_Cm1327 position. Functional studies reveal that SNORD104 depletion abolishes 2'Ome at 28S_Cm1327 without affecting basal translation or cell viability, but enhances both under crizotinib exposure. Moreover, SNORD104 knockdown attenuates caspase activation and PARP cleavage during treatment, supporting reduced cell death. Altogether, our findings support a role for snoRNA-guided rRNA modification as a novel non-genomic mechanism in early adaptive responses to crizotinib therapy in LUAD.

PMID 43052254
阅读全文 →
PubMedPlant, cell & environment2026-11-19

Heavy Metal Uptake, Signalling, Detoxification and Environmental Adaptation in Plants: Mechanistic Insights and Emerging Mitigation Strategies.

El-Beltagi Hossam S HS, Hassan Karim M KM, Rezk Adel A AA, Shehata Wael F WF et al.

Heavy metal contamination has emerged as a widespread environmental problem that threatens ecosystem functioning, biodiversity and plant performance across natural and managed ecosystems. Toxic elements, including cadmium (Cd), lead (Pb), nickel (Ni), zinc (Zn), aluminium (Al) and other potentially hazardous metals, can accumulate in plant tissues, disrupting growth, development, physiological processes and cellular homoeostasis while posing risks to ecological and human health through trophic transfer. Understanding the mechanisms underlying metal uptake, transport, sequestration and detoxification is therefore essential for increasing plant resilience in metal-stressed environments. This review synthesises current knowledge of plant responses to heavy metal stress, integrating physiological, biochemical, cellular, genetic and molecular mechanisms that contribute to tolerance and adaptation. Particular attention is given to the factors regulating metal accumulation and distribution within plants, including species and genotypic variation, soil physicochemical properties, rhizosphere processes, microbial associations and environmental conditions. This review also evaluates recent advances in strategies to mitigate heavy metal toxicity, including nutrient-based approaches, soil amendments, beneficial microorganisms, biostimulants, phytoremediation technologies, rhizosphere engineering and nanotechnology-assisted interventions. Emerging evidence indicates that plant responses to heavy metals are highly species-specific and strongly shaped by plant-microbe-soil interactions, emphasising the importance of integrated and context-dependent management approaches. Despite substantial progress, significant knowledge gaps remain regarding the regulation of metal partitioning, long-term adaptive responses, cross-tolerance mechanisms and the identification of critical thresholds for maintaining plant health under diverse environmental conditions. Future research integrating multiomics technologies, microbiome engineering, molecular breeding and precision remediation strategies will provide new opportunities to strengthen plant resilience and reduce the ecological risks associated with heavy metal contamination. By consolidating current advances and future directions, this review offers a comprehensive framework for understanding plant adaptation to heavy metal stress and for supporting sustainable ecosystem management in contaminated environments.

PMID 43053517
阅读全文 →
PubMedFrontiers in neurology2026-11-18

Neurotoxicity associated with ALK inhibitors in the treatment of non-small cell lung cancer: an analysis of the FAERS database.

Lin Chutong C, Tang Jizheng J, Ning Yingze Y, Qiang Guangliang G

ALK inhibitors (ALKis) have substantially improved outcomes in ALK-positive non-small cell lung cancer (NSCLC). Neurological adverse events (AEs) remain clinically relevant, but their reporting patterns and reported time-to-onset (TTO) characteristics in routine pharmacovigilance require further characterization. Neurological AE reports recorded with five ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib) were extracted from FAERS (Q1 2004-Q1 2025). Reporting disproportionality was evaluated at the preferred-term (PT) level using the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN). TTO analyses were restricted to reports with evaluable timing information, and exploratory subgroup analyses characterized reporting-signal patterns by age, sex, and reporter type. The final analysis included 1,473 report-level reports and 2,274 PT-level neurological AE records; one report could contain more than one PT. Lorlatinib, ceritinib, brigatinib, crizotinib, and alectinib had 29, 15, 12, 9, and 9 PTs, respectively, that met all three disproportionality criteria. Among the 1,473 reports, 577 (39.17%) had evaluable TTO information. Recorded onset times among these evaluable reports were more concentrated in the earlier period after treatment initiation, but this distribution does not estimate incidence, absolute risk, or hazard among all exposed patients. This pharmacovigilance analysis identifies drug-specific patterns of reported neurological AEs and reported TTO among ALK inhibitors. The findings support clinical awareness and hypothesis generation, but they do not establish causality or comparative clinical safety and should be evaluated in studies with exposure denominators and control of confounding.

PMID 43047343
阅读全文 →
PubMedBlood advances2026-11-18

Nodal peripheral T-cell lymphoma: a prognostic index developed by the T-cell project.

Luminari Stefano S, Shokun Nazarii N, Conte Luana L, Filonenko Kateryna K et al.

To characterize real-world treatment patterns and outcomes in nodal peripheral T-cell lymphoma (PTCL) and to develop and externally validate a contemporary clinical prognostic model, we analyzed patients prospectively registered in the International T-Cell Project 2 (TCP2). Between January 2018 and January 2026, 1,465 patients with PTCL were registered; 959 with nodal PTCL by the 2016 WHO classification (PTCL not otherwise specified (PTCL-NOS), systemic anaplastic large-cell lymphoma (ALCL; ALK-positive or ALK-negative), and T-follicular helper lymphoma (TFHL)) were analyzed. The primary endpoint was 2-year progression-free survival (PFS); the model was externally validated in the TCP1 cohort (n = 1,016). The cohort comprised 396 PTCL-NOS (41%), 263 TFHL (27%), 211 ALK-negative ALCL (22%), and 89 ALK-positive ALCL (9%). First-line therapy was CHOEP in 340 (37%), CHOP in 260 (29%), and brentuximab vedotin-CHP in 139 (15%); 156 underwent consolidative stem cell transplantation. After a median follow-up of 25.3 months, 2-year PFS and overall survival were 35.3% and 54.3%, respectively. In multivariate analysis, diagnosis other than ALCL, age ≥65 years, ECOG performance status ≥2, thrombocytopenia, extranodal involvement, and elevated LDH were independently associated with inferior PFS. A six-variable score using these factors stratified patients into 3 risk groups - low (score 0-1), intermediate (2-3), and high (4-6) with 2-year PFS, 65%, 33%, and 16% respectively (P < .001) and was confirmed in the TCP1 validation cohort. Outcomes for nodal PTCL remain poor with current therapy; the externally validated TCP score offers a contemporary, complementary tool for risk stratification and identification of patients at high risk of treatment failure. ClinicalTrials.gov NCT03964480, NCT01142674.

PMID 43050693
阅读全文 →
PubMedJCO global oncology2026-11-18

Molecular Testing and Genomic Landscape of Non-Small Cell Lung Cancer in Malaysia: Real-World Evidence From a Resource-Limited Setting.

Cheo Seng Wee SW, Tan Shirin Hui SH, Ong Ai Rene AR, Chong Jenny Kha Mieng JKM et al.

Molecular profiling is essential for the management of non-small cell lung cancer (NSCLC), yet access to comprehensive testing remains inequitable in low- and middle-income settings. We evaluated real-world molecular testing patterns and the genomic landscape of NSCLC in Sarawak, Malaysia, to identify gaps in precision oncology implementation. We retrospectively analyzed patients diagnosed with NSCLC between January 2017 and December 2023 at a tertiary center. Demographic, clinicopathologic, and molecular testing data were analyzed using descriptive and multivariable analyses. Among 577 NSCLC cases, 76.6% presented with advanced disease. The cohort was enriched with substantial representation of indigenous populations (Iban 23.4%, Bidayuh 10.9%). Molecular testing was performed in 86.7% overall and 91.2% of stage IV cases. However, most testing relied on single-gene assays (81.6%), whereas only 8.5% underwent next-generation sequencing (NGS), revealing a diagnostic paradox of high testing uptake but limited genomic depth. PD-L1 testing was performed in 19.2% of patients. Epidermal growth factor receptor (EGFR) mutations were the most common alteration (52.9%), followed by anaplastic lymphoma kinase (ALK) fusions (6.3%). Never-smoking status (odds ratio [OR], 8.68, P < .001) and age ≥70 years (OR, 1.91, P = .043) were independently associated with EGFR mutations. Exploratory multivariable analysis suggested higher odds of ALK positivity among patients of Bidayuh and other ethnicity although this estimate was imprecise because of the small number of ALK-positive cases. High testing rates alone are insufficient to deliver precision oncology. Reliance on limited assays risks underdetection of actionable genomic alterations and perpetuates inequities in access to targeted therapies and clinical trials. Expanding equitable access to comprehensive genomic profiling and integrating it into routine cancer care are essential for closing this implementation gap and advancing precision oncology in under-represented populations.

PMID 43050624
阅读全文 →
PubMedModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2026-11-18

CD40 expression is highly sensitive and specific for differentiating between classic Hodgkin lymphoma and ALK-negative anaplastic large cell lymphoma.

Spivey Theresa T, Jungbluth Achim A, Serrette Rene R, Zhou Ting T et al.

Distinguishing classic Hodgkin lymphoma (CHL) from anaplastic large cell lymphoma (ALCL) can be diagnostically challenging, particularly in cases where lineage-defining markers are diminished or absent. Both entities are CD30-positive lymphomas and may share overlapping morphologic features, including atypical cytology and disrupted immunophenotypic expression. While B-cell markers such as PAX5, OCT2, and BOB1 are used to support B-cell lineage in CHL, their inconsistent expression can limit diagnostic confidence. In this study, we evaluated the performance of CD40 immunohistochemistry (IHC) in a cohort of CD30-positive lymphomas. CD40, a receptor involved in B-cell activation and differentiation, has been previously reported in Hodgkin/Reed-Sternberg cells, but its diagnostic utility in this setting has not been comprehensively assessed in clinical practice or in this differential. Our findings show that CD40 IHC demonstrates 98.6% sensitivity and 100% specificity for CHL, including in diagnostically ambiguous cases such as PAX5-negative CHL and ALK-negative ALCL with a null phenotype. Notably, CD40 was consistently negative in all ALCL cases, including those requiring a clinicopathologic consensus diagnosis, underscoring its potential as a reliable marker of B-cell lineage. Although background staining in histiocytes and dendritic cells may complicate interpretation, careful morphologic correlation helps mitigate this issue. These results support the inclusion of CD40 into diagnostic panels for CD30-positive lymphomas with unclear lineage differentiation. Further comparative studies may help define its role alongside other B-cell markers and expand its utility across a broader range of lymphoid neoplasms.

PMID 43051594
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多aluminium hydroxide